Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > worth repeating

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 11, 2024 7:14pm

80 Views

Post# 36307436

RE:worth repeating

jeez, Canaduh, what exactly is "accelerated approval" ready..??

YOu sure know how to spin a poorly spelled yarn. ONCY does not have anything that is AA ready... what they have is guidance from the FDA, that after approx 2 years of the next mBC Phase II trial, IF the results are significantly positive, only then could ONCY apply for AA.

It is NOT a given
It is NOT ready.

2 years awy... I fail to understand how you fail to appreciate these details...

Now, where is that partnership/buyout... or is that next year now.?

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project